الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 144 |  |  |
| | | from | 144 | | |
Abstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are linked to hepatocellular carcinoma (HCC), which is one of the most prevalent and deadly cancers. At the end of 2018, the incidence of HCC has risen to 19.7% of all cancer patients (25,399 cases). Egypt has the world’s second highest rate of HCC, which can be attributed to the hepatitis C virus’s high prevalence and consequences (HCV). The most significant approaches to lower the risk of HCC in Egypt include active surveillance for HCC, HCV screening programs, and the early beginning of antiviral medication with new potent direct acting antivirals (DAAs) for patients with chronic HCV infection. The 2018 incidence statistics were gathered from the cancer registries in Aswan, Damietta, and Minia, and derived using a weighted/simple average of the most recent local population rates for 2018. In Egypt, HCC is the leading cause of cancer-related death (32.35 % of the total cancer deaths).